Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.

Advances in Therapy
Takashi KadowakiMakoto Ueno

Abstract

Healthy eating is a critical aspect of the prevention and management of type 2 diabetes (T2DM). Disrupted eating patterns can result in poor glucose control and increase the likelihood of diabetic complications. Teneligliptin inhibits dipeptidyl peptidase-4 activity for 24 h and suppresses postprandial hyperglycemia after all three daily meals. This interim analysis of data from the large-scale post-marketing surveillance of teneligliptin (RUBY) in Japan examined eating patterns and their relationship with metabolic parameters and diabetic complications. We also examined whether eating patterns affected safety and efficacy of teneligliptin. We analyzed baseline data from survey forms collected in RUBY between May 2013 and June 2017, including patient characteristics, metabolic parameters, and eating patterns (eating three meals per day or not; timing of evening meal) before teneligliptin treatment was initiated. Safety and efficacy of 12 months' teneligliptin (20-40 mg/day) treatment was assessed. Data from 10,532 patients were available for analysis. Most patients who did not eat three meals per day (n  =757) or who ate their evening meal after 10 PM (n  =206) were 64 years old or younger. At baseline, glycated hemoglobin (HbA...Continue Reading

References

Oct 27, 2009·Endocrine Reviews·Oren Froy
Mar 30, 2012·The American Journal of Clinical Nutrition·Rania A MekaryFrank B Hu
Jun 14, 2013·The American Journal of Clinical Nutrition·Rania A MekaryFrank B Hu
Jun 26, 2013·The New England Journal of Medicine·Rena R WingSusan Z Yanovski
Jul 31, 2013·Journal of Clinical Lipidology·Harold E BaysVarman T Samuel
Oct 8, 2013·Chronobiology International·Sirimon ReutrakulKristen L Knutson
Nov 14, 2013·Journal of the American Pharmacists Association : JAPhA
Nov 14, 2013·Journal of the American Pharmacists Association : JAPhA
Jul 1, 2011·Obesity Research & Clinical Practice·Maki SatoKumpei Tokuyama
Mar 19, 2014·Diabetes Research and Clinical Practice·L GuariguataJ E Shaw
May 21, 2014·Journal of Diabetes Investigation·Takashi Kadowaki, Kazuoki Kondo
Feb 25, 2015·Journal of Gastroenterology·Sumio WatanabeUNKNOWN Japan Society of Hepatology
Dec 8, 2015·Obesity Facts·Volkan YumukUNKNOWN Obesity Management Task Force of the European Association for the Study of Obesity
Apr 8, 2016·Diabetologia·UNKNOWN European Association for the Study of the Liver (EASL)UNKNOWN European Association for the Study of Obesity (EASO)
May 25, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·W Timothy GarveyUNKNOWN Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines
Nov 26, 2016·Science·Satchidananda Panda
Dec 10, 2016·Journal of Diabetes Investigation·Eiichi ArakiTakashi Kadowaki
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

SAS
RUBY

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.